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Abstract
Background Primary pediatric extraspinal sacrococcygeal ependymoma (ESE) is a very rare disease, poorly described in liter-
ature, whose diagnostic, therapeutic, and follow-up approach is still controversial.
Methods We describe six cases of pediatric ESE treated at Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)
centers in Italy since 1983, with a review of the literature.
Results All six patients had primary sacrococcygeal disease (two presacral and four subcutaneous) with median age of 10 years.
Three patients were males, and two of them are metastatic at diagnosis; 3/6 had myxopapillary ependymoma grade I and 3/6 had
classic ependymoma grade II. Five patients underwent surgical resection with complete removal only in one case with
coccygectomy. Adjuvant chemoradiotherapy was administered to one metastatic patient obtaining a complete remission. Two
patients relapsed at 3 and 8 years from diagnosis: they were treated with salvage chemotherapy (high-dose sequential chemo-
therapy with myeloablative regimen in one case), surgery, and radiotherapy achieving complete remission (CR). All six patients
are in complete continuous remission (CCR) at a median follow-up of 12.8 years.
Conclusions Pediatric patients with this peculiar disease need to be referred to specialized pediatric cancer centers that can
provide multidisciplinary treatment after a centralized pathology review. Our experience highlights the role of chemotherapy
and radiotherapy in adjuvant and relapse setting. The final prognosis is relatively optimistic, but with a careful follow-up due to
the high risk of recurrence.
Keywords Pediatric ependymoma . Coccygectomy . Radiotherapy . Chemotherapy
Introduction
Ependymoma is the third most common pediatric brain tumor,
originating mainly from the walls of the ventricular system; it
accounts for only 6% of intracranial gliomas, but for more than
60% of spinal cord tumors [1, 2]. Of all primary brain tumors,
ependymomas have the greatest propensity to occur outside the
central nervous system (CNS). Extraspinal ependymoma is a
very rare entity that may develop at various different sites. It
most often originates from the subcutaneous tissue of the
sacrococcygeal area with no demonstrable connection to the
spinal cord; more rarely, it can originate from the presacral/
pelvic region. Very uncommon sites include the mediastinum,
lung, and liver [3–5]. Extraspinal sacrococcygeal ependymoma
(ESE) is a very rare tumor, accounting for less than 5% of all
spinal ependymomas [6]. Some case reports of pediatric ESE in
the literature describe primary tumors of the skin and soft tissue
in the sacrococcygeal region, with no evidence of any connec-
tion to the spinal cord [7, 8].
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Historical background
ESE was first described by Mallory in 1902 [9].
Some studies report a slight male predominance [10], while
others describe a balanced gender distribution [11, 12].
Bimodal peaks in the disease’s incidence have been suggested
for ESE in the sacral region, one peak at less than 8 years of age
and one in the fourth decade of life [13]; some authors have
reported that ESE occurs more than intraspinal ependymoma in
younger patients [8, 14]. Patients’ ages at diagnosis range from
3 months to > 80 years, with a mean of 26 years [10, 12, 15].
ESE typically occurs in two characteristic regions: the soft
subcutaneous tissue posterior to the sacrum or the presacral
space anterior to the sacrum, in the retrorectal recess. Under
the age of 18 years, the sacrococcygeal area is the more com-
mon primary site; ovarian ESE becomes more frequent beyond
the adult age.
The largest pediatric series of pediatric ESEwas reported in
2014 [11] with seven cases and a median age of 7.4 years
(range 3 weeks–17 years), but without any clinical informa-
tion related to treatment (Table 1).
Clinical presentation
If the lesion lies posterior to the sacrum, its peculiar presenting
symptoms are a slow-growing mass in the intergluteal fold,
which is occasionally painful and often misdiagnosed as a
pilonidal cyst or other benign tumors. If the origin is pelvic,
the ESE is usually larger on discovery, a palpable mass detect-
able on pelvic or rectal examination associatedwith bowel and
bladder dysfunction and, rarely, signs/symptoms of nerve root
involvement such as saddle anesthesia, loss of ankle jerk, or
poor rectal sphincter tone [10, 12, 13, 16].
Diagnosis
The histogenesis of these lesions is very controversial, but
three different hypotheses are worth exploring; the first is that
it might originate from the coccygeal medullary vestige, an
ependymal cell-lined cavity that is a remnant of the neural
tube, over the tip of the coccyx [16]. This hypothesis would
be supported by the observation that most of these types of
ESE are of the myxopapillary variant, which is characteristic
of an ependymoma arising from the filum terminale [17]. This
theory was confirmed by Bale and Maiorana, who found post-
coccygeal ependymal rests in embryos and in 10/15 random
infant necropsies [18, 19]. Other authors suggest that the tu-
mor develops from a residual, congenitally ectopic ependymal
cell originating from the filum terminale. This hypothesis is
supported by the correlation with defects in the neural arch
(such as spina bifida), found in around 20–30% of patients
with ependymoma [20–23]. A third hypothesis is that a germ
cell origin with exclusive neuroectodermal differentiation has
also been considered, which could explain the disease’s ovar-
ian, mesovarian, and mediastinal localizations [22] .
The majority of ESE are myxopapillary grade I WHO like
their spinal counterpart [6]. Immunohistochemical reactions
usually show positivity for GFAP, EMA, and negativity for
Olig2.
Classic ependymoma (grade II WHO) is more frequent in
ESE located in the ovary/mediastinum [6]. Unlike CNS
ependymomas, adult ESE are often strongly and diffusely
positive for estrogen and progesterone, thus providing an op-
portunity for hormone-based therapies.
Many other diseases need to be ruled out in the differential
diagnosis, including pilonidal cyst, benign ependymal rest,
teratoma, lipoma, chordoma, myxoid chondrocarcinoma, met-
astatic mucoid carcinoma, metastatic carcinoid, clear cell car-
cinoma, neurofibroma, and inflammatory diseases [24–26].
Management
Standard management options for pediatric ESE are not
known; it seems that the chances of survival improve with
gross total resection to prevent any local relapse. Complete
removal is technically feasible for most postsacral tumors,
but a combined approach (neurosurgical and pelvic) may be
necessary for presacral tumors. Surgical coccygectomy is rec-
ommended if the tumor adheres to the bone [17] and repeated
excisions for local recurrences achieve good results. Some
authors [13, 27] have recommended coccygectomy as part
of the primary surgical treatment. Aktuğ et al. [27] conducted
a review on 22 pediatric sacrococcygeal ESE reported since
1963, finding that there were no local recurrences in cases
whose coccyx had been removed (four patients, with a mean
follow-up of 3 years), whereas 5/7 patients who had not un-
dergone coccygectomy experienced a local relapse.
Sonneland et al. reported that ESE tend to metastasize more
frequently than their intrameningeal spinal counterpart [10].
Metastases to the lung, pleura, bone, lymph nodes, and sub-
cutaneous tissues are attributed to an easier access to vascular
and lymphatic vessels [28], and a prolonged and very careful
follow-up is consequently recommended. Metastatic spread
correlates with the specific extraspinal localization, subcuta-
neous tumor being at greater risk of metastases than presacral
disease, which is more likely to relapse locally [29]. There
may be a lengthy interval (even 10–20 years) between the
primary lesion’s detection and resection, and the development
of distant metastases, as in other low-grade malignancies; sev-
eral reports describe distant metastases being found 10–
20 years after a patient’s primary diagnosis [12, 16, 17, 28].
Table 1 lists all cases of pediatric ESE reported in the liter-
ature since 1963. Cimino [11] described seven pediatric
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patients with myxopapillary ESE, none of whom developed
metastases or recurrences, whereas 2/4 children with spinal
tumors experienced a recurrence after surgery and radiothera-
py. In an earlier study on 23 evaluable patients with ESE,
Helwig [16] found that 4 (17%) developed metastases; the
youngest of these patients, a 17-year-old female, underwent
surgical excision of the primary tumor, but developed pleural
and lung dissemination 6 months later and died 5 years after
her diagnosis. There are another three reports [30–32] of chil-
dren aged 18 months, 11 months, and 4 years whose ESE
metastasized to the inguinal lymph nodes: one of them had a
component of anaplastic ependymoma but surgery alone
achieved a CCR, and a 4-year-old child experienced a lung
relapse 19 years after diagnosis and was treated with surgery,
achieving a CR at 1 year. Another report [33] described a 10-
year-old child with multifocal localizations (in the pilonidal
area and left buttock), who achieved CR after surgical exci-
sion alone. Kramer [14] described a 15-year-old male with
subcutaneous ESE treated with surgical excision at diagnosis
who experienced two local relapses (9 and 19 years after di-
agnosis), then a third local relapse (20 years later) associated
with inguinal metastatic lymph nodes, treated with surgery
and focal radiotherapy (50.4 Gy).
The role of radiotherapy in pediatric ESE is not clear.
Adjuvant radiotherapy has been recommended after subtotal
resections, in the case of inoperable tumor, after the removal
of recurrent lesions, or in the event of metastatic dissemination
[13, 17], but conclusive data on its real effectiveness are lack-
ing. Some authors recommend a total dose of 50 Gy to the
lesion [13, 20] which is unlikely to cause myelopathy. There
have been a few cases in which moderate doses of irradiation
(30–45 Gy) after incomplete surgery have obtained satisfac-
tory progression-free survival rates and symptom relief [34],
while other authors have reported discouraging effects of ra-
diotherapy [14, 35].
The role of chemotherapy is also still unclear. Vaigawala
[28] used an aggressive combination of chemotherapeutic
agents in a relapsing patient. Yu et al. [36] administered meth-
otrexate and doxorubicin to a relapsing patient with pleural
metastases, achieving unsatisfactory results, and Morantz [13]
used polychemotherapy for two relapsing pediatric patients,
reporting no evidence of relief. On the other hand, Rao [37]
used neoadjuvant chemotherapy consisting of 3 cycles of
cisplatin/etoposide and bleomycin in a 16-month-old female
with a large pelvic mass, achieving a more than 50% reduction
in the size of the lesion, plus another three adjuvant courses,
achieving a CR. Hwang [38] used topotecan and carboplatin
(based on an in vitro chemosensitivity test), inducing a partial
response, followed by complete tumor resection and adjuvant
doxorubicin/gemcitabine, with no tumor recurrence. Mogler
[5] administered imatinib (based on c-kit expression on the
tumor tissue) and carboplatin/etoposide chemotherapy for a
huge pelvic tumor, obtaining its stabilization.
The use of hormonal suppressive agents has been largely
unexplored. There are some reports of hormonal therapy being
used for spinal [39–41] and extraaxial ependymomas.
Neoadjuvant gonadotropin-releasing hormone treatment in a
patient with large ovarian ependymoma (with a positive nu-
clear reactivity for estrogen, progesterone, and androgen re-
ceptors) obtained a reduction in tumor size [42]. A combina-
tion of tamoxifen and etoposide for a relapsing spinal
myxopapillary ependymoma was able to stabilize the tumor
[43]. Therapies inhibiting specific molecular pathways have
been sporadically assessed: imatinib for lung metastases of
sacrococcygeal ependymoma had no effect, while administer-
ing sorafenib for 1 year achieved disease stabilization [44].
Prognosis and outcome
Presacral tumors are more prone to local recurrence [13, 45],
with an incidence of recurrence estimated at 60% and a high
mortality rate (75%). It is worth noting, however, that these
percentages come from reports dating from a time before cen-
tralized pathology reviews were in use, and they are conse-
quently likely to be overestimated. In the case of subcutaneous
tumors, local recurrences are less frequent (25% at 15 years),
but distant metastases are more common [46].
Exemplary case description
Here, we describe six cases of pediatric ESE treated in Italy
since 1983 collected by reviewing the medical records of pa-
tients referred to our department or at AIEOP Italian centers.
Histologic diagnosis were reviewed by retrieving the blocks
and centralizing them at the Italian Pathology reference center.
Parents signed an informed consent. Immunohistochemistry
for GFAP, EMA (dot-like), and Olig2, proliferation index
evaluated with Ki-67, and hormonal expression of androgens
or estrogen/progesterone receptors were evaluated.
The patients’ clinical characteristics are shown in Table 2.
Three of the six patients were male, and the patients’median
age at diagnosis was 10 years (range 4–16 years). All six patients
had primary sacrococcygeal disease (two in the presacral region
and four in the subcutaneous tissue). Two had metastases at the
time of their diagnosis, which involved the inguinal lymph
nodes, acetabulum, ischium, and sacral vertebrae in one case
and the parauterine region in the other. A growing palpable
painless intergluteal lesion was the presenting symptom in five
patients, while enuresis and sacral pain were reported only for
one metastatic patient with presacral tumor. The coccyx was
infiltrated in two cases, but coccygectomy was only performed
in one; five patients underwent primary surgery, achieving com-
plete removal in only one. Of the two patients withmetastases on
presentation, one initially underwent biopsy for diagnostic
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purposes, followed by wide tumor resection at the end of the
treatment, and the other had extensive, complete surgical resec-
tion of the primary site at diagnosis. A centralized pathology
review was feasible in four out of six cases and confirmed an
original diagnosis of grade I myxopapillary ependymoma in
two cases and grade II classic ependymoma in two patients,
originally diagnosed as neuroepithelial tumor and malignant
myoepithelioma respectively. Myxopapillary ependymoma
showed tumor cells arranged around vessels with mucoid de-
generation. Classic ependymomas were characterized by co-
lumnar tumor cells arranged around infrequent central lumen
and perivascular pseudorosettes.
Immunohistochemistry showed positivity for GFAP and
EMA (dot-like) and negativity for Olig2 (Fig. 1). Proliferation
index evaluated with Ki-67 ranged from 2 to 20%; in detail, it
was equal to 25 and 20% in the metastatic patient at relapse and
at diagnosis respectively. It could be hypothesized that there is a
correlation between metastatic disease and high level of Ki-67,
but the number of patient is too low; therefore, a confirmation
and a larger study are needed. Estrogen and progesterone anti-
gens were expressed in one case.
Adjuvant therapy was only administered to one metastatic
patient, with standard-dose chemotherapy (vincristine,
carboplatin, epirubicin, actinomycin-D, ifosfamide, etoposide),
which achieved a partial response, followed by radiotherapy
(40.4 Gy) to the pelvis, including the acetabulum, ischium,
and sacral vertebrae; the patient subsequently underwent wide
resection of the residual lesion. Two of the six patients experi-
enced a recurrence (3 and 8 years after their primary diagnosis):
– One (patient 6) had subcutaneous disease at diagnosis
treated with incomplete surgery, subsequently developed
an inguinal lymph node metastasis, and was treated with
inguinal lymphadenectomy and salvage chemotherapy
(alternating 3 cycles of cisplatin 30 mg/m2 and etoposide
150 mg/m2 on days 1–3 with 3 cycles of doxorubicin
20 mg/m2 on days 1–3, vincristine 1.5 mg/m2 and cyclo-
phosphamide 330 mg/m2 on days 1, 8, and 15).
Fig. 1 Tumors are characterized
by cuboidal and elongated tumor
cells arranged in a papillary
fashion around vascularized
stromal cores. Neoplastic cells are
GFAP positive and show dot-like
EMA positivity
a 
b 
Fig. 2 a Patient 3: computed Tomography imaging at relapse: right
hypodense hemipelvic lesion with iliac adenopathies. Multiple bilateral
parenchymal lung nodules. b MRI of subcutaneous intergluteal
localization at diagnosis
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– The other (patient 3) had metastatic parauterine lesion at
diagnosis and experienced a local recurrence with neo-
plastic iliac thrombosis, lung and broad ligament metas-
tases, and retroperitoneal and mediastinal adenopathies
(Fig. 2); she received high-dose sequential chemotherapy
(see Table 3) with a partial response of the pelvic lesions
and pulmonary/mediastinal metastases, followed by
myeloablative melphalan with peripheral autologous
stem cell transplantation, then pelvic radiotherapy
(54 Gy). Both of these relapsing patients achieved CR.
All six patients are alive in CCR with a median follow-up
of 12.8 years. The two girls given pelvic radiotherapy are
currently being treated with estrogen-progestin replace-
ment therapy for iatrogenic amenorrhea.
Conclusion
While adult data suggest a very marginal role for chemother-
apy, more favorable results have been reported in the pediatric
context. The numbers involved in pediatric series are too small
for any definitive conclusions to be drawn on this issue; how-
ever, our experience, albeit on a very small series, points to a
role for chemotherapy, in both the neo/adjuvant setting and at
relapse, since a partial remission was achieved with sequential
high-dose chemotherapy before radiotherapy. Although the
final prognosis for pediatric ESE is relatively optimistic, pa-
tients need to be followed up carefully for many years due to
the risk of recurrence.
Moreover, it is crucial that patients with rare oncological
pediatric diseases such as ESE are referred to specialized pe-
diatric cancer centers that can provide for a centralized reliable
diagnosis as well as the surgical and complementary treat-
ments warranted in an updated multidisciplinary view.
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